Category: gene editing including CRISPR

New Year, New Fund, New Opportunities in Bio + Health



2021 saw higher than ever funding of startups, continued maturation of the tech-enabled bio and healthcare landscape, and new platforms and business models that propelled growing levels of adoption and scale amongst both upstarts and traditional players. Accordingly, we nearly …

The post New Year, New Fund, New Opportunities in Bio + Health appeared first on Andreessen Horowitz.

Upgrading cell and gene therapy “software” for safety; Pharma picks their PROTAC horses; The first healthtech giant; and more



This post first appeared as an issue of the a16z Bio Newsletter. Subscribe to stay on top of the latest trends in bio and healthcare.

IN THIS EDITION

  • Of vaccines and vaccinology, in COVID-19 and beyond: How to build a

The post Upgrading cell and gene therapy “software” for safety; Pharma picks their PROTAC horses; The first healthtech giant; and more appeared first on Andreessen Horowitz.